Zobrazeno 1 - 10
of 331
pro vyhledávání: '"William A. Zamboni"'
Autor:
Lauren S.L. Price, Judith N. Rivera, Andrew J. Madden, Leah B. Herity, Joseph A. Piscitelli, Savannah Mageau, Charlene M. Santos, Jose R. Roques, Bentley Midkiff, Nana N. Feinberg, David Darr, Sha X. Chang, William C. Zamboni
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
Background: Minibeam radiation therapy is an experimental radiation therapy utilizing an array of parallel submillimeter planar X-ray beams. In preclinical studies, minibeam radiation therapy has been shown to eradicate tumors and cause significantly
Externí odkaz:
https://doaj.org/article/740570a053e546c4b20b6d47a8927c6a
Publikováno v:
Antibodies, Vol 10, Iss 3, p 30 (2021)
Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers
Externí odkaz:
https://doaj.org/article/86bf972f21754c5aacaf27bbb3da639c
Autor:
Norman E. Sharpless, Charles M. Perou, Gary L. Johnson, William C. Zamboni, Jian Jin, Austin J. Combest, Soren M. Johnson, James S. Duncan, Martin C. Whittle, Adam D. Pfefferle, Patrick M. Dillon, David B. Darr, Jerry E. Usary, Patrick J. Roberts
PDF file, 53K, MP1U Dosing Regimens.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06aab9f024e8516676b9d1a778432315
https://doi.org/10.1158/1078-0432.22455326.v1
https://doi.org/10.1158/1078-0432.22455326.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Supplementary Fig. S3. Profiling of collagen in basal-like C3-TAg model and claudin-low T11 model at baseline and at 96 h after administration of PLD or NL-doxo at 6 mg/kg I.V. x 1 via tail vein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc71154b91cc2042f3442bd51e4b8470
https://doi.org/10.1158/1078-0432.22456287.v1
https://doi.org/10.1158/1078-0432.22456287.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Supplementary Data. Table S1. Product information from FormuMax Scientific, Inc. Table S2. Doxorubicin AUC0-96h in plasma, tissues, and tumor in the C3-TAg model and the T11 model after PLD or NL-doxo administration at 6 mg/kg I.V. x 1 via tail vein
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d5eef07a6263cca0d09627ab18668a7
https://doi.org/10.1158/1078-0432.22456296.v1
https://doi.org/10.1158/1078-0432.22456296.v1
Autor:
William C. Zamboni, Charles M. Perou, Andrew C. Dudley, Arlin B. Rogers, Teresa K. Tarrant, C. Ryan Miller, Nana Nikolaishvili-Feinberg, Stephanie Cohen, Bentley R. Midkiff, Jamie L. Jordan, Alain Valdivia, Mark Ross, Charlene M. Santos, David B. Darr, Gina Song
Purpose: Tumor cells are surrounded by a complex microenvironment. The purpose of our study was to evaluate the role of heterogeneity of the tumor microenvironment in the variability of nanoparticle (NP) delivery and efficacy.Experimental Designs:C3(
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ccbc13d16ad8b3f6c8192576b91d968a
https://doi.org/10.1158/1078-0432.c.6523266.v1
https://doi.org/10.1158/1078-0432.c.6523266.v1
Autor:
Norman E. Sharpless, Charles M. Perou, Gary L. Johnson, William C. Zamboni, Jian Jin, Austin J. Combest, Soren M. Johnson, James S. Duncan, Martin C. Whittle, Adam D. Pfefferle, Patrick M. Dillon, David B. Darr, Jerry E. Usary, Patrick J. Roberts
Purpose: Anticancer drug development is inefficient, but genetically engineered murine models (GEMM) and orthotopic, syngeneic transplants (OST) of cancer may offer advantages to in vitro and xenograft systems.Experimental Design: We assessed the act
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12662f1438dbf6c4e5e9ee67c13703ba
https://doi.org/10.1158/1078-0432.c.6522992
https://doi.org/10.1158/1078-0432.c.6522992
Publikováno v:
Pharmaceutics, Vol 13, Iss 1, p 114 (2021)
Major developments in nanomedicines, such as nanoparticles (NPs), nanosomes, and conjugates, have revolutionized drug delivery capabilities over the past four decades. Although nanocarrier agents provide numerous advantages (e.g., greater solubility
Externí odkaz:
https://doaj.org/article/2baed0c966ee4478b580c87ac524e198
Publikováno v:
Cancer drug resistance (Alhambra, Calif.)
Standard small molecule and nanoparticulate chemotherapies are used for cancer treatment; however, their effectiveness remains highly variable. One reason for this variable response is hypothesized to be due to nonspecific drug distribution and heter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::620da8617da973d22a88901bcd99fe55
http://europepmc.org/articles/PMC8597952
http://europepmc.org/articles/PMC8597952
Autor:
Marije Risselada, Keith E Linder, Emily Griffith, Brittney V Roberts, Gigi Davidson, William C Zamboni, Kristen M Messenger
Publikováno v:
PLoS ONE, Vol 12, Iss 10, p e0186018 (2017)
The objectives of this study were to assess the pharmacokinetics and safety of subcutaneously delivered carboplatin in poloxamer 407 in rats. Carboplatin (5mg/rat) in 0.5ml poloxamer 407 (1.0 ml total volume) was administered subcutaneously in a righ
Externí odkaz:
https://doaj.org/article/9bd661108468477daad6307d782e68a3